BCL2 and renal cell carcinoma: We screened a library of 292 structurally diverse, medicinally active, and cell-permeable small molecules (including inhibitors of key cancer-relevant targets—for example, VEGFR, MET, EGFR, PDGFR, PI3K, CDK, and apoptosis-inducing molecules such as BCL2, TP53, MDM2, survivin) in 8 human RCC cell lines (VHL WT: ACHN, SN12C, TK10, UO31, CAKI-1, and VHL Null: 786-0, 769-P, A498; Table S1 [note: CAKI-1 has clear cell pathology]).27